Tyler Dylan-Hyde Sells 66,000 Shares of Crispr Therapeutics AG (CRSP) Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 66,000 shares of Crispr Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total value of $1,849,980.00. Following the completion of the transaction, the insider now owns 25,204 shares in the company, valued at $706,468.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.64, for a total value of $822,320.00.
  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.75, for a total value of $15,225.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $22.72, for a total value of $704,320.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.90, for a total value of $283,500.00.

Shares of Crispr Therapeutics AG (CRSP) opened at $29.73 on Friday. Crispr Therapeutics AG has a 52-week low of $11.63 and a 52-week high of $30.96.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The business had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The firm’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.77) EPS. analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after purchasing an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $193,000. Ark Investment Management LLC acquired a new stake in Crispr Therapeutics during the 2nd quarter worth about $206,000. Moloney Securities Asset Management LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $235,000. Finally, Creative Planning acquired a new stake in Crispr Therapeutics during the 4th quarter worth about $243,000. 21.91% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently weighed in on CRSP. Piper Jaffray Companies reissued a “buy” rating and issued a $22.75 price objective (down previously from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. BidaskClub raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. Finally, SunTrust Banks reissued a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.81.

WARNING: “Tyler Dylan-Hyde Sells 66,000 Shares of Crispr Therapeutics AG (CRSP) Stock” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3147016/tyler-dylan-hyde-sells-66000-shares-of-crispr-therapeutics-ag-crsp-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.